Skip to content

Internet Explorer is no longer supported by this website.

For optimal browsing we recommend using Chrome, Firefox or Safari.
Heart icon (animated) heart icon (static)

Jump to:

Lung Cancer Initiative

Lung Cancer Initiative
at Johnson & Johnson
Lung Cancer Initiative
at Johnson & Johnson

Lung cancer is the leading cause of cancer deaths globally, and it is often detected too late, with more than half of cases metastasizing by the time they are first diagnosed1… but there is hope.

With patients at the heart of everything we do, The Lung Cancer Initiative (LCI) at Johnson & Johnson was formed in 2018 to unleash the full potential of lung cancer science to help change the trajectory of this complex disease.

As an R&D engine, the LCI takes a multidisciplinary approach in bringing together the unparalleled expertise, technology, scale and reach across Johnson & Johnson within its Pharmaceutical, Medical Device and Consumer Health sectors, and works with collaborators worldwide to advance innovations that aim to create more effective and personalized treatments for lung cancer with the goal to improve patient outcomes.

Leadership

The LCI leadership team is a small, but diverse entrepreneurial team of global experts in clinical, pharmaceutical, engineering, surgical and early detection sciences dedicated to preventing, intercepting and curing lung cancer.

More From Johnson & Johnson

Advancing New Healthcare Solutions Through Collaboration
Reimagining the Way Healthcare Is Delivered
Our Vision: The Elimination of Cancer

1 GLOBOCAN 2020: SEER 18 2010–2016; SEER Cancer Stat Facts

This site uses cookies as described in our Cookie Policy. Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
Close cookie banner icon
Back to top
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue